ScinoPharm Taiwan Ltd (台灣神隆) yesterday said it expects sales to grow steadily this year, but added that it plans to diversify its business from generic active pharmaceutical ingredients (API) to contract manufacturing and research services in a bid to avoid an intense price competition in the generic API market.
The Tainan-based pharmaceutical company reported revenue of NT$3.52 billion (US$114.3 million) for last year, inching up 0.2 percent from a year earlier.
However, thanks to cost controls, net profit rose 4.9 percent annually to NT$443 million, or earnings per share of NT$0.56, the company said.
Revenue from generic API accounted for 65 percent of total revenue, maintaining its top ranking, while combined revenue from contract manufacturing and research services made up 34 percent, company data showed.
ScinoPharm this year expects to gain regulatory approval in the US to supply generic APIs for a treatment for breast cancer and benign prostatic hyperplasia, as well as approvals in China and Japan for two other generic APIs, ScinoPharm marketing and sales vice president Portia Lin (林靜雯) told an investors’ conference in Taipei.
“However, we found that the prices of generic APIs fell significantly due to intense competition, and we could not win over our peers in countries with lower manufacturing costs, such as India and China,” Lin said.
ScinoPharm’s revenue from generic APIs last year fell 5.6 percent annually to NT$75.8 million, but revenue from contract manufacturing and research services jumped 10.4 percent and 64.7 percent annually to NT$17.2 million and NT$22.4 million respectively, company data showed.
Instead of seeking more API clients, the company plans to expand its contract manufacturing and research services this year, in the hope of boosting revenue contribution from the two segments to 40 percent of overall revenue.
This year, the company aims to focus more on the markets in Japan and China, which offer faster growth opportunities, compared with slowing growth in the US and Europe, where opportunities are further constrained by large-scale mergers and acquisitions in the pharmaceuticals sector, ScinoPharm said.
ScinoPharm shares yesterday rose 1.14 percent to NT$26.7 in Taipei. They have advanced 10.56 percent since the beginning of this year, compared with the broader market’s 9.41 percent rise over the same period.
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Chizuko Kimura has become the first female sushi chef in the world to win a Michelin star, fulfilling a promise she made to her dying husband to continue his legacy. The 54-year-old Japanese chef regained the Michelin star her late husband, Shunei Kimura, won three years ago for their Sushi Shunei restaurant in Paris. For Shunei Kimura, the star was a dream come true. However, the joy was short-lived. He died from cancer just three months later in June 2022. He was 65. The following year, the restaurant in the heart of Montmartre lost its star rating. Chizuko Kimura insisted that the new star is still down
While China’s leaders use their economic and political might to fight US President Donald Trump’s trade war “to the end,” its army of social media soldiers are embarking on a more humorous campaign online. Trump’s tariff blitz has seen Washington and Beijing impose eye-watering duties on imports from the other, fanning a standoff between the economic superpowers that has sparked global recession fears and sent markets into a tailspin. Trump says his policy is a response to years of being “ripped off” by other countries and aims to bring manufacturing to the US, forcing companies to employ US workers. However, China’s online warriors
RSS